On July 16, 2024, the French Ministry of Labor, Health and Solidarity published the merged 2024 List of acts outside the nomenclature financed under MERRI G03.

In July 2024, the National Institute for Health and Disability Insurance (INAMI-RIZIV) approved a new agreement (Convention) allowing reimbursement for percutaneous CT-guided ablation of renal, hepatic, pulmonary, and bone tumors. The agreement will come into force on November 1, 2024, and will be valid until October 31, 2029.

On July 15, 2024, the Austrian Institute for HTA (AIHTA) published three decision support documents that provide recommendations regarding the inclusion of new medical interventions in the catalog of individual medical services (MEL) for reimbursement, as well as two updates to previous decision support documents. The decisions relate to cardiovascular, peripheral vascular, interventional radiology, neuromodulation, and endocrine technology groups.

In late June – mid-July 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for another three completed projects. The projects were dedicated to the topics of care concept for patients with hidradenitis suppurativa (acne inversa), the use of webcams in neonatal intensive care units, and improving the pharmacovigilance of innovative therapies.

On June 26, 2024, the Norwegian Directorate of Health published its proposal to change the process of including new diseases in newborn screening. The key objective is making the process more dynamic, which requires regulatory and administrative amendments.

On June 19, 2024, the Order SND/606/2024, of June 13, came into force. This Order, among other things, creates the Advisory Committee for the Common Package of Benefits in the Area of Genetics.

On June 21, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the determined funding priorities for healthcare research projects (eight topics) and clinical guidelines (three topics).

On June 26, 2024, the document "Changes and innovations in the 2025 LKF model" (Änderungen und Neuerungen in den LKF-Modellen 2025) was published. The document summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes mainly concern e-health, interventional radiology, pulmonary and airways, and surgical procedures fields.

On July 2, 2024, the revised EBM (German Uniform Evaluation Standard) catalog for the third quarter of 2024 was published. The changes introduced mainly concern updating the content of several EBM sections with the respective comments and/or clarifications and introducing the new EBM codes for several companion diagnostics tests, for follow-up and evaluation of the “Kranus Lutera” health app, and for the services provided within the co-funded study on bronchoscopic lung volume reduction in severe pulmonary emphysema using thermal ablation (rp-RL BTVA).

On July 1, 2024, the annual call for proposals to the UK National Screening Committee (UK NSC) was launched. During the call, stakeholders can propose potential new screening topics or modifications of existing screening programs. The deadline for applications is September 30, 2024.

On June 19, 2024, the Order SND/606/2024, of June 13, came into force. This Order, among other things, amends Annexes I, II, III, VI, and VII of Royal Decree 1030/2006, of September 15, which establishes the Common Package of Benefits of the National Health System and the procedure for its update. The changes mostly concern in-vitro diagnostics, ENT, pulmonary and airways, cardiovascular, and some other fields.

On July 1, 2024, the National Institute for Health and Disability Insurance (INAMI/RIZIV) introduced a new agreement (Convention), which allows permanent reimbursement for molecular biology tests by next-generation sequencing (NGS) in oncology and hemato-oncology. The tests were reimbursed temporarily in the context of the pilot Convention from 2019. Fifty-one new pseudo-nomenclature codes with tariffs were introduced. The pseudocode descriptions specify the indication, while certain biomarkers and reimbursement conditions are mentioned as notes to the code.